Search results for "direct cost"

showing 10 items of 59 documents

On-line Italian register for severe/non-controlled asthma

2013

Background Severe/Non-controlled asthma (SNCA) is a crucial challenge for physicians and a socio-economic burden for National Health Services (NHS). In Italy more than 50% of costs for asthma (1-2% of total NHS expenditure) are due to SNCA and moreover, within the European Community Respiratory Health Survey, Italy was the country with the lowest % of ICS daily use (29%) and with the highest % of subjects with uncontrolled asthma despite treatment (67% vs an overall European mean of 47%). Despite few data from very selected centers, in our country a precise estimate of the epidemiological figures and the disease related costs for SNCA is not available. Thus, we aimed at instituting of an on…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPediatricseducation.field_of_studybusiness.industryImmunologyPopulationAlternative medicineDiseasemedicine.diseaseUncontrolled asthmaIndirect costsEnvironmental healthEpidemiologyPoster PresentationmedicineImmunology and AllergyeducationbusinessRespiratory healthAsthmaClinical and Translational Allergy
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

From Sustainable Development to Personalised Healthcare. The Role of Institutions in the Sustainable Development of the Healthcare Systems

2015

Abstract The current issues concerning healthcare institutions are generated by: aging of the population; the increase in prevalence of non-communicable diseases, even in low/medium income countries; the continuous increase of indirect costs generated by chronic diseases; the necessity of new- patient-specific oriented therapies; the need of translation of fundamental research into practice; need of applicability of prevention strategies; an important segment of the working population becomes inactive; migration of healthcare professionals. An essential condition for the sustainable development of any community is the health and the maintenance of the health of its population, and it is ess…

Sustainable developmentIndirect costsEconomic growtheducation.field_of_studyHealth professionalsbusiness.industryHealth carePopulationWorking populationBusinessBusiness managementeducationHealthcare systemManagement of Sustainable Development
researchProduct

The Individual-level Productivity Costs of Physical Inactivity

2023

Abstract Purpose: This study estimated the long-term individual-level productivity costs of physical inactivity. Methods: The data were drawn from the Northern Finland Birth Cohort 1966, to which the productivity cost variables (sick leaves and disability pensions) from Finnish registries were linked. Individuals (N = 6261) were categorized into physical activity groups based on their level of physical activity, which was measured in three ways: 1) self-reported leisure-time moderate- to vigorous-intensity physical activity (MVPA) at 46 yr old, 2) longitudinal self-reported leisure-time MVPA at 31–46 yr old, and 3) accelerometer-measured overall MVPA at 46 yr old. The human capital approach…

activity monitorjoutilaisuustuottavuushuman capital approachphysical activityPhysical Therapy Sports Therapy and Rehabilitationliikuntaregister-based datacohort studyhenkinen pääomaOrthopedics and Sports Medicineindirect costskohorttitutkimusfyysinen aktiivisuus
researchProduct

Early Treatment in HCV: Is it a Cost-Effective Option from the Italian Perspective?

2016

Background: The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing HCV-infected patients.Methods: The incremental cost-utility analysis was carried out to quantify the benefits of the early treatment approach in HCV subjects. A Markov simulation model including direct and indirect costs and health outcomes was developed from Italian National Healthcare Service and societal perspective. 5,000 Monte Carlo simulations were performed on two distinct scenarios: Standard of Care (SoC) which includes 14.000 Genotype 1 patients in Italy treated with innovative interferon-free in the Fibrosis stage 3 and 4 (F3-F4) v…

education.field_of_studymedicine.medical_specialtyActuarial sciencebusiness.industryPopulationTime horizonIndirect costsSystematic reviewEpidemiologyHealth careMedicineeducationbusinessIncremental cost-effectiveness ratiohealth care economics and organizationsReimbursementSSRN Electronic Journal
researchProduct

Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation

2014

OBJECTIVE: We sought to evaluate the association between constipation severity, productivity losses and healthcare utilization in a national sample of Italian patients with chronic non-organic constipation (CC). METHODS: We enrolled 878 outpatients with CC. Clinical and demographic data were collected by physicians during clinical examinations. Patients completed a self-administered questionnaire (Patient Assessment of Constipation-Symptoms, PAC-SYM; Work Productivity and Activity Impairment; healthcare utilization, and Symptoms Checklist 90 Revised - Somatization Scale, SCL-90 R). RESULTS: Mean PAC-SYM score was 1.62 ± 0.69. Mean weekly sick time due to constipation was 2.7 ± 8.6 h and pro…

medicine.medical_specialtyConstipationChronic constipation; Cost-of-illness study; Direct cost; Functional constipation; Healthcare utilization; Indirect cost; Irritable bowel syndrome; Productivity loss; Oncology; Gastroenterologymacromolecular substancesIndirect costsdirect costMedicineIn patientIntensive care medicineProductivitycost-of-illness studyIrritable bowel syndromeirritable bowel syndromeChronic constipation; cost-of-illness study; direct cost; functional constipation; healthcare utilization; indirect cost; irritable bowel syndrome; productivity lossChronic constipationChronic constipationbusiness.industryGastroenterologyhealthcare utilizationfunctional constipationOriginal Articlesmedicine.diseaseproductivity lossOncologyHealthcare utilizationindirect costPhysical therapyFunctional constipationmedicine.symptombusinessUnited European Gastroenterology Journal
researchProduct

Cost-effectiveness and cost-utility analysis of the treatment of emotional disorders in primary care: psicap clinical trial. description of the sub-s…

2018

Introduction: In the primary care (PC) setting in Spain, the prevalence of emotional disorders (EDs) such as anxiety, depression and somatoform disorder is high. In PC patients, these disorders are not always managed in accordance with the recommendations provided by clinical practice guidelines, resulting in major direct and indirect economic costs and suboptimal treatment outcomes. The aim is to analyze and compare the cost-effectiveness and cost-utility of group-based psychological therapy versus treatment as usual (TAU). Methods: Multicenter, randomized controlled trial involving 300 patients recruited from PC centers in Madrid, Spain, with symptoms or possible diagnosis of anxiety, moo…

medicine.medical_specialtyCost effectivenesslcsh:BF1-990QALYslaw.inventionprimary care03 medical and health sciencesIndirect costs0302 clinical medicineRandomized controlled triallawmedicinePsychologyClinical Study Protocol030212 general & internal medicinecost-utilityGeneral PsychologyCost–utility analysisEmocionstransdiagnostic cognitive-behavioral therapy030227 psychiatryPatient Health QuestionnaireClinical triallcsh:PsychologyMoodemotional disordersPhysical therapyAnxietymedicine.symptomPsychology
researchProduct

Epidemiology and social costs of hip fracture.

2018

Hip fracture is an important and debilitating condition in older people, particularly in women. The epidemiological data varies between countries, but it is globally estimated that hip fractures will affect around 18% of women and 6% of men. Although the age-standardised incidence is gradually falling in many countries, this is far outweighed by the ageing of the population. Thus, the global number of hip fractures is expected to increase from 1.26 million in 1990 to 4.5 million by the year 2050. The direct costs associated with this condition are enormous since it requires a long period of hospitalisation and subsequent rehabilitation. Furthermore, hip fracture is associated with the devel…

medicine.medical_specialtyFinancing PersonalPopulationDisease03 medical and health sciencesIndirect costs0302 clinical medicineAge DistributionEpidemiologyMedicineHumans030212 general & internal medicineHospital CostseducationDepression (differential diagnoses)General Environmental Science030222 orthopedicseducation.field_of_studyHip fracturebusiness.industryHip FracturesIncidence (epidemiology)IncidenceLength of Staymedicine.diseaseHospitalizationSarcopeniaQuality of LifeGeneral Earth and Planetary SciencesbusinessHip fracture Social cost EpidemiologyDemographyInjury
researchProduct

Klinische und ökonomische Evaluation der Inanspruchnahme zahnärztlicher Leistungen im Ausland

2003

Purpose During the past decade German patients developed an increasing tendency to dental health tourism in countries outside the European Union. The present investigation aimed at evaluating both clinical and economic outcome of dental care in these countries with regard to German directive standards. Methods Based on physical examinations performed by the Medizinische Dienst der Krankenversicherung Rheinland-Pfalz in the context of reimbursement or regress requests after dental care in countries outside the European Union, an individual treatment concept was designed and its direct costs from the patient's perspective were estimated according to German standards. Furthermore, the clinical…

medicine.medical_specialtyHealth economicsbusiness.industryPublic Health Environmental and Occupational HealthMEDLINEContext (language use)Directivelanguage.human_languageGermanIndirect costsNursingFamily medicinelanguagemedicinemedia_common.cataloged_instanceEuropean unionbusinesshealth care economics and organizationsReimbursementmedia_commonDas Gesundheitswesen
researchProduct

Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospit…

2012

Invasive fungal disease (IFD) causes increasing morbidity and mortality in haematological cancer patients. Reliable cost data for treating IFD in German hospitals is not available. Objective of the study was to determine the institutional cost of treating the IFD. Data were obtained by retrospective chart review in German hospitals. Patients had either newly diagnosed or relapsed acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS). Direct medical cost was calculated from hospital provider's perspective. A total of 108 patients were enrolled at 5 tertiary care hospitals, 36 IFD patients and 72 controls. The vast majority of IFD patients (74%) were diagnosed with invasive aspergil…

medicine.medical_specialtyMyeloidbusiness.industryMyelodysplastic syndromesRetrospective cohort studyDermatologyGeneral MedicineAspergillosismedicine.diseaseIndirect costsInfectious DiseasesInvasive fungal diseasePharmacotherapymedicine.anatomical_structureInternal medicinemedicineYoung adultbusinessIntensive care medicineMycoses
researchProduct